Ulu, B. U. Et Al. 2022. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. JOURNAL OF CHEMOTHERAPY , vol.34, no.3 , 190-198.

Ulu, B. U., Dal, M. S., Hindilerden, I. Y., Akay, O. M., MEHTAP, Ö., Buyukkurt, N., ... Hindilerden, F.(2022). Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. JOURNAL OF CHEMOTHERAPY , vol.34, no.3, 190-198.

Ulu, Bahar Et Al. "Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients," JOURNAL OF CHEMOTHERAPY , vol.34, no.3, 190-198, 2022

Ulu, Bahar U. Et Al. "Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients." JOURNAL OF CHEMOTHERAPY , vol.34, no.3, pp.190-198, 2022

Ulu, B. U. Et Al. (2022) . "Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients." JOURNAL OF CHEMOTHERAPY , vol.34, no.3, pp.190-198.

@article{article, author={Bahar Uncu Ulu Et Al. }, title={Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients}, journal={JOURNAL OF CHEMOTHERAPY}, year=2022, pages={190-198} }